HomeCompareNXRT vs MCK

NXRT vs MCK: Dividend Comparison 2026

NXRT yields 4.00% · MCK yields 0.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCK wins by $16.2K in total portfolio value· pulled ahead in Year 8
10 years
NXRT
NXRT
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full NXRT calculator →
MCK
MCK
● Live price
0.38%
Share price
$860.19
Annual div
$3.28
5Y div CAGR
66.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.3K
Annual income
$10,761.37
Full MCK calculator →

Portfolio growth — NXRT vs MCK

📍 MCK pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNXRTMCK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NXRT + MCK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NXRT pays
MCK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NXRT
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
MCK
Annual income on $10K today (after 15% tax)
$32.41/yr
After 10yr DRIP, annual income (after tax)
$9,147.16/yr
At 15% tax rate, MCK beats the other by $8,382.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NXRT + MCK for your $10,000?

NXRT: 50%MCK: 50%
100% MCK50/50100% NXRT
Portfolio after 10yr
$36.2K
Annual income
$5,830.28/yr
Blended yield
16.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCK right now

NXRT
Analyst Ratings
3
Buy
6
Hold
1
Sell
Consensus: Hold
Price Target
$27.00
-46.0% upside vs current
Range: $27.00 — $27.00
Altman Z
0.8
Piotroski
6/9
MCK
Analyst Ratings
1
Strong
24
Buy
6
Hold
Consensus: Buy
Price Target
$982.38
+14.2% upside vs current
Range: $900.00 — $1,085.00
Altman Z
5.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NXRT buys
0
MCK buys
0
No recent congressional trades found for NXRT or MCK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNXRTMCK
Forward yield4.00%0.38%
Annual dividend / share$2.00$3.28
Payout ratio50%50%
1-year div growth5%0%
5-year div CAGR5%66.7%
Portfolio after 10y$28.0K$44.3K
Annual income after 10y$899.19$10,761.37
Total dividends collected$6.4K$22.6K
Payment frequencyquarterlyquarterly
SectorREITHealthcare
Analyst consensusHoldBuy
Analyst price target$27.00$982.38

Year-by-year: NXRT vs MCK ($10,000, DRIP)

YearNXRT PortfolioNXRT Income/yrMCK PortfolioMCK Income/yrGap
1$11,120$420.00$10,764$63.56+$356.00NXRT
2$12,357$458.31$11,624$106.59+$733.00NXRT
3$13,721$499.76$12,617$179.33+$1.1KNXRT
4$15,227$544.58$13,803$303.26+$1.4KNXRT
5$16,885$593.02$15,286$516.89+$1.6KNXRT
6$18,713$645.34$17,248$891.81+$1.5KNXRT
7$20,724$701.81$20,023$1,567.70+$701.00NXRT
8← crossover$22,938$762.73$24,260$2,835.35$1.3KMCK
9$25,372$828.41$31,310$5,352.05$5.9KMCK
10$28,047$899.19$44,263$10,761.37$16.2KMCK

NXRT vs MCK: Complete Analysis 2026

NXRTREIT

NXRT is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NXRT shares.

Full NXRT Calculator →

MCKHealthcare

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Full MCK Calculator →
📬

Get this NXRT vs MCK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NXRT vs SCHDNXRT vs JEPINXRT vs ONXRT vs KONXRT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.